On June 5, Fuyuan Pharmaceutical announced that it had recently received the "Drug Clinical Trial Approval Notice" for Ketoprofen Patch approved and issued by the State Drug Administration. The drug's indications include a variety of pain and inflammation-related diseases, such as low back pain, osteoarthritis and rheumatoid arthritis.

Ketoprofen patches have been approved in countries or regions such as Japan, Italy, and Portugal, but as of June 2025, no manufacturer has imported them for sale. According to data from MinEnet, the sales of ketoprofen patches in the Chinese market in 2024 will be about 5 million yuan, of which sales in urban public hospitals and county-level public hospitals will be 2.33 million yuan, and sales in urban physical pharmacies and online pharmacies will be 2.67 million yuan. The product still needs to go through the relevant approval procedures before it can be launched, and there is still uncertainty as to whether it can be finally approved for listing.

In the first quarter of 2025, Fuyuan Pharmaceutical achieved revenue of 830 million yuan and net profit attributable to shareholders of the parent company of 131 million yuan.

https://finance.eastmoney.com/a/202506053422974815.html